As the growth of drug expenses continues to outpace other expenses, integrated delivery networks (IDNs) are increasingly deploying sophisticated tools to monitor, manage, and influence prescribing behaviors. Our most recent 2024 IDN Oncology Trend Survey—scheduled for release at the end of this month—specifically looked at the use of high-cost drug review or committees because the majority of IDNs (~70%) use one of these mechanisms to consider both inpatient and outpatient treatments, which includes cancer drugs.
The Figure below illustrates the types and prevalence of tools IDNs with high-cost drug reviews or committees use to monitor these drugs.
Figure. Share of IDNs With High-Cost Drug Reviews That Deploy Various Tools (2024; N = 112) Includes only IDNs that have high-cost drug reviews (69% of IDNs), and 1% of respondents were unsure.
Source: HMP Market Access Insights 2024 IDN Oncology Trend Report.
Abbreviations: EHR, electronic health record. IDN, integrated delivery network.
Manufacturers should be aware of how the variety of tools IDNs deploy to manage prescribing may influence prescribing patterns, and we look forward to sharing additional insights later this month when we release our full 2024 IDN Oncology Trend report!
The ATOPP Summit covered a range of cutting-edge topics, including the shift toward administering cellular therapies to patients in community oncology settings.
Emma Bijesse, Daniel BuchenbergerWelcome to our Monthly Insight Series July 2024 edition! This month we discuss our 2024 research regarding the ever-rising integration across vertical payers’ health plans, PBMs, and SPs, including around manufacturer contracting.
Chris Van DenburgWelcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.
Ashutosh Sheth